• November 26, 2021

    Tchaikapharma High Quality Medicines obtained marketing authorisations for the Republic of Kosovo for the medicinal products Bilamcar 8 mg/5 mg; 16 mg/5 mg hard capsules and Ceftriaxon-Tchaikapharma 1 g; 2 g powder for solution for injection/infusion. The first deliveries are planned for early 2022.   Thus, the number of registered products of the company in […]

  • November 22, 2021

    The latest medicinal products to receive Marketing Authorization from the BDA and expand Tchaikapharma’s rich and diverse portfolio are:   – Tamaira Plus 5 mg/5 mg/12.5 mg; 5 mg/5 mg/25 mg; 10 mg/5 mg/25 mg hard capsules (with APIs ramipril, amlodipine and hydrochlorothiazide).   The medicinal product is indicated for the treatment of high blood […]

  • July 7, 2021

    The first half of this year did not bring much of a stir in stock trading as a consequence of both the development of the pandemic and the slow recovery of the economy.   However, at the end of June this year, the Bulgarian Stock Exchange had a public company with a market capitalization of […]

  • May 21, 2021

    Tchaikapharma Highquality Medicines, a flagship company on the Bulgarian pharma market, started trading shares on the Bulgarian Stock Exchange (BSE) on 21 May 2015. On today’s date exactly 6 years ago, the initial offering price per share was BGN 3.59, and on 21 May 2021 – BGN 14.10. This represents a growth of 292.757% over […]

  • February 23, 2021

    SOFIA (Bulgaria), February 23 (SeeNews) – Bulgarian drug maker Tchaikapharma High Quality Medicines [BUL:7TH] said that its shareholders have approved its plan to borrow up to 14 million euro ($17.2 million) in order to finance the construction of a new production plant just outside Sofia.   The proposal was supported by all shareholders present at […]